Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) EBIT Margin (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EBIT Margin for 2 consecutive years, with 35767.86% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin changed N/A to 35767.86% in Q3 2025 year-over-year; TTM through Sep 2025 was 16092.81%, a 1217131.0% decrease, with the full-year FY2023 number at 284.16%, changed N/A from a year prior.
  • EBIT Margin was 35767.86% for Q3 2025 at Mereo BioPharma, up from 2099.8% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 35767.86% in Q3 2025 to a low of 2099.8% in Q2 2025.